Cell-based delivery of oncolytic viruses: A new strategic alliance for a cancer

被引：86

作者：

Power, Anthony T. ^{[1
]}

Bell, John C. ^{[1
]}

机构：

[1] Univ Ottawa, Ctr Canc Therapeut, Ottawa Hlth Res Inst, Ottawa Hosp,Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 1C4, Canada

来源：

MOLECULAR THERAPY | 2007年 / 15卷 / 04期

关键词：

D O I：

10.1038/sj.mt.6300098

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Recent years have seen tremendous advances in the development of exquisitely targeted replicating virotherapeutics that can safely destroy malignant cells. Despite this promise, clinical advancement of this powerful and unique approach has been hindered by vulnerability to host defenses and inefficient systemic delivery. However, it now appears that delivery of oncolytic viruses within carrier cells may offer one solution to this critical problem. In this review, we compare the advantages and limitations of the numerous cell lineages that have been investigated as delivery platforms for viral therapeutics, and discuss examples showing how combined cell-virus biotherapeutics can be used to achieve synergistic gains in antitumor activity. Finally, we highlight avenues for future preclinical research that might be taken in order to refine cell-virus biotherapeutics in preparation for human trials.

引用

收藏

页码：660 / 665

页数：6

相关论文

共 66 条

[21]

Hirasawa K, 2003, CANCER RES, V63, P348

[22] The plasticity of dendritic cell responses to pathogens and their components [J].

Huang, Q ;

Liu, DY ;

Majewski, P ;

Schulte, LC ;

Korn, JM ;

Young, RA ;

Lander, ES ;

Hacohen, N .

SCIENCE, 2001, 294 (5543) :870-875

[23] The role of ICPO-null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma [J].

Hummel, JL ;

Safroneeva, E ;

Mossman, KL .

MOLECULAR THERAPY, 2005, 12 (06) :1101-1110

[24]

IANKOV I, MOL THER, V15, P114

[25] Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses [J].

Ikeda, K ;

Ichikawa, T ;

Wakimoto, H ;

Silver, JS ;

Deisboeck, TS ;

Finkelstein, D ;

Harsh, GR ;

Louis, DN ;

Bartus, RT ;

Hochberg, FH ;

Chiocca, EA .

NATURE MEDICINE, 1999, 5 (08) :881-887

[26] Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors [J].

Jevremovic, D ;

Gulati, R ;

Hennig, I ;

Diaz, RM ;

Cole, C ;

Kleppe, L ;

Cosset, FL ;

Simari, RD ;

Vile, RG .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 287 (02) :H494-H500

[27] Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF [J].

Kim, J. H. ;

Oh, J. Y. ;

Park, B. H. ;

Lee, D. E. ;

Kim, J. S. ;

Park, H. E. ;

Roh, M. S. ;

Je, J. E. ;

Yoon, J. H. ;

Thorne, S. H. ;

Kirn, D. ;

Hwang, T. H. .

MOLECULAR THERAPY, 2006, 14 (03) :361-370

[28] Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses [J].

Komarova, S ;

Kawakami, Y ;

Stoff-Khalili, MA ;

Curiel, DT ;

Pereboeva, L .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) :755-766

[29] Humoral immune responses against minute virus of mice vectors [J].

Lang, Susanne I. ;

Giese, Nathalia A. ;

Rommelaere, Jean ;

Dinsart, Christiane ;

Cornelis, Jan J. .

JOURNAL OF GENE MEDICINE, 2006, 8 (09) :1141-1150

[30] Discovery of the first virus, Tobacco mosaic virus:: 1892 or 1898? [J].

Lecoq, H .

COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE III-SCIENCES DE LA VIE-LIFE SCIENCES, 2001, 324 (10) :929-933

← 1 2 3 4 5 6 7 →